Cybin Shares Surge on $50M Capital Raise as Phase 3 Depression Trial Nears Enrollment Finish

Cybin raises $50M in public offering to fund pivotal Phase 3 trial of HLP003 for treatment-resistant depression, with top-line results expected in Q4 2026. Stock rises 8% despite dilution fears.

Financing deals in the biotech sector often trigger a selloff as dilution bites. For Cybin, the opposite happened. The psychedelics-focused developer closed a $50 million public equity offering on June 25, and its stock promptly jumped over 8% to $6.51 on Friday, extending a month-long rally that has lifted the shares by roughly 47% from their early June trough.

The placement involved the issuance of just over 10.3 million shares at $4.85 apiece. Cantor and Barclays acted as joint bookrunners on the transaction, pocketing a combined $3 million in fees for their role. Management made clear the proceeds have a tight itinerary: the bulk will bankroll the company's lead programs through critical data readouts.

At the forefront is HLP003, a deuterated psilocin analogue being tested in the pivotal Phase 3 APPROACH study for treatment-resistant depression. The trial has already enrolled 86% of its target patients and remains on schedule to deliver top-line results in the fourth quarter of 2026. The U.S. Food and Drug Administration has granted HLP003 breakthrough therapy designation, underscoring the unmet need in this patient population.

Behind HLP003, part of the fresh capital flows to HLP004, a deuterated DMT molecule in Phase 2 for generalized anxiety disorder, and to earlier-stage work on HLP005, plus general corporate expenses. Cybin also disclosed encouraging Phase 2 data for HLP003 that preceded the pivotal study: after 12 months of treatment, the mean MADRS depression-score drop was roughly 23 points, with a 100% response rate and a 71% remission rate.

Investors are betting that the financing buys enough runway to reach that Q4 2026 inflection point. The stock's recent run from a 52-week low of $3.76 — touched in early June — has nearly doubled the price, though it still sits more than 30% below its 12-month peak of $9.83. The placement, rather than diluting confidence, appears to have been read as a necessary bridge to registration.

For a company operating in the volatile psychedelics space, the combination of a funded late-stage trial and strong early efficacy signals is rare. Whether the APPROACH study can replicate the Phase 2 remission numbers — and whether regulators will ultimately grant approval — remains the open question that will determine Cybin's next move.